17th Jun 2026 07:00
Faron Pharmaceuticals Ltd | Company announcement | June 17, 2026 at 09:00:00 EEST
Standard form for notification of major holdings
| NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA) | |||||
| 1. Identity of the issuer:FARON PHARMACEUTICALS OY | |||||
| 2. Reason for the notification (please tick the appropriate box or boxes):? An acquisition or disposal of shares or voting rights? An acquisition or disposal of financial instruments? An event changing the breakdown of shares or voting rights? Other (please specify): Click here to enter text. | |||||
| 3. Details of person subject to the notification obligation: | |||||
| Name:Bank of America Corporation | City and country of residence:Wilmington, DE, United States of America | ||||
| 4. Full name of shareholder(s) (if different from 3.):- | |||||
| 5. Date on which the threshold was crossed or reached:12.6.2026 | |||||
| 6. Total positions of person(s) subject to the notification obligation: | |||||
| % of shares and voting rights (total of 7.A) | % of shares and voting rights through financial instruments (total of 7.B) | Total of both in % (7.A + 7.B) | Total number of shares and voting rights of issuer | ||
| Resulting situation on the date on which threshold was crossed or reached | 0.12 | 9.99 | 10.11 | 206,411,888 | |
| Position of previous notification (if applicable) | 0.13 | 10.07 | 10.20 | ||
| 7. Notified details of the resulting situation on the date on which the threshold was crossed or reached: | |||||||||
| A: Shares and voting rights | |||||||||
| Class/type ofsharesISIN code (if possible) | Number of shares and voting rights | % of shares and voting rights | |||||||
| Direct(SMA 9:5) | Indirect(SMA 9:6 and 9:7) | Direct(SMA 9:5) | Indirect(SMA 9:6 and 9:7) | ||||||
| FI4000153309 | 0 | 246,335 | 0 | 0.12 | |||||
| - | - | - | - | - | |||||
| - | - | - | - | - | |||||
| SUBTOTAL A | 246,335 | 0.12 | |||||||
| B: Financial Instruments according to SMA 9:6a | |||||||||
| Type of financial instrument | Expirationdate | Exercise/ Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights | ||||
| Rights of Use | n/a | n/a | n/a | 20,374,993 | 9.87 | ||||
| Swaps | 15/10/2027 | n/a | Cash | 245,294 | 0.12 | ||||
| - | - | - | - | - | - | ||||
| SUBTOTAL B | 20,620,287 | 9.99 | |||||||
| 8. Information in relation to the person subject to the notification obligation (please tick the applicable box):? Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.? Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity: | |||
| Name | % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| 9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of Click here to enter a date. | |||
| 10. Additional information: | |||
Done at London, United Kingdom on 15.6.2026.
Related Shares:
Faron Pharmaceuticals